Injectable Drug Delivery Devices Market Report 2026

Injectable Drug Delivery Devices Market Overview

• Injectable Drug Delivery Devices market size has reached to $54.3 billion in 2025 • Expected to grow to $79.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Increasing Prevalence Of Chronic Diseases To Drive Market Growth • Market Trend: Advancements In Wearable And Smart Injector Technologies Enhance Patient-Centric Drug Delivery • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Injectable Drug Delivery Devices Market?

Injectable Drug Delivery Devices refer to medical devices designed to administer medications directly into the body through injections. Injectable drug delivery devices are used for various routes of drug administration, such as intravenous, subcutaneous, intradermal, intra-peritoneal, and intra-muscular. The main types of injectable drug delivery devices are conventional injectables, pre-filled syringes, auto-injectors, and pen injectors. The prefilled syringes are packaged with the fixed needle that contains single-dose vaccines or other medications. The injectable drug delivery devices offer applications such as autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, and others that are used by various end-users such as hospitals and clinics, home healthcare settings, pharmaceutical and biotechnological companies, research laboratories, and others.

What Is The Injectable Drug Delivery Devices Market Growth Forecast?

The injectable drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $79.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing shift toward self-administration devices, rising demand for personalized drug delivery, expansion of biologic drug pipelines, growing investments in smart injection technologies, increasing adoption of home healthcare solutions. Major trends in the forecast period include increasing adoption of prefilled and safety syringes, rising demand for autoinjectors and pen injectors, growing use of home-based injectable therapies, expansion of wearable and implantable infusion pumps, enhanced focus on dose accuracy and patient safety.

Global Injectable Drug Delivery Devices Market Segmentation

1) By Type: Syringes, Injectors, Pump 2) By Application: Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Pain Management, Respiratory Therapy, Other Applications 3) By End-user: Hospitals And Clinics, Home Healthcare Settings, Pharmaceutical And Biotechnological Companies, Research Laboratories, Other End Users Subsegments: 1) By Syringes: Conventional Syringes, Prefilled Syringes, Safety Syringes 2) By Injectors: Autoinjectors, Pen Injectors, Needle-Free Injectors 3) By Pumps: Insulin Pumps, Ambulatory Infusion Pumps, Implantable Pumps

What Is The Driver Of The Injectable Drug Delivery Devices Market?

The rising prevalence of chronic diseases is expected to propel the growth of the injectable drug delivery devices market. Chronic disease refers to a form of illness that lasts for three months or more and can deteriorate with time. Injectable drug delivery devices offer a reliable and convenient method for the administration of medications over extended periods. These devices can enhance patient adherence to prescribed treatment regimens, ensuring the effective management of chronic conditions and ultimately leading to better health outcomes. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the injectable drug delivery devices industry going forward.

Key Players In The Global Injectable Drug Delivery Devices Market

Major companies operating in the injectable drug delivery devices market are Becton Dickinson and Company, Baxter International, Gerresheimer AG, Catalent Inc., Antares Pharma, Owen Mumford, West Pharmaceutical Services Inc., B. Braun Melsungen AG, Ypsomed AG, AptarGroup Inc., Nemera, Teleflex Medical, Medtronic, Caplin Steriles Limited, Hovione Technology, Jiangsu Delfu Medical Device Co. Ltd., Terumo Corporation, Roche, Sorrel Medical, Novo Nordisk

Global Injectable Drug Delivery Devices Market Trends and Insights

Major companies operating in the injectable drug delivery devices market are focusing on developing advanced solutions, such as wearable and smart injectors, to improve patient convenience, enhance adherence, and support self-administration of complex therapies. Wearable and smart injectors are innovative systems designed to deliver accurate doses of medications including biologics and large-volume formulations while reducing discomfort, minimizing user error, and improving overall treatment experience. For instance, in January 2025, Becton, Dickinson and Company, a US-based medical technology company, introduced multiple next-generation devices such as the BD Accuspray Nasal Spray System, BD Hylok Glass Prefillable Syringe, BD Effivax Glass Prefillable Syringe, BD Libertas Wearable Injector, BD Evolve On-body Injector, BD Physioject Disposable Autoinjector, and BD Vystra Disposable Pen. These solutions feature user-friendly designs for self-administration, precise and consistent dosing for biologics and vaccines, compatibility with diverse drug formulations, and wearable formats that support large-volume delivery, all while ensuring sterility and safety through disposable components. The launch underscores the industry’s shift toward advanced, patient-centric injectable drug delivery systems aimed at improving adherence, comfort, and therapeutic outcomes.

What Are Latest Mergers And Acquisitions In The Injectable Drug Delivery Devices Market?

In May 2025, Amneal Pharmaceuticals, Inc., a US-based provider of generic, specialty, and biosimilar pharmaceutical products, entered a strategic collaboration with Apiject Systems, Corp., to advance resilient, high-volume U.S. sterile manufacturing through innovative BFS injectable solutions. The partnership aims to boost the production of sterile drug products made with BFS by using Amneal’s manufacturing strength and Apiject’s advanced BFS technology, which will help make the supply chain stronger, produce more products, and improve the ability to create injectables, eye treatments, and inhalations. Apiject Systems, Corp. is a US-based medical technology company specializing in advanced drug delivery systems, including BFS-based injectable platforms.

Regional Outlook

North America was the largest region in the injectable drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Injectable Drug Delivery Devices Market?

The injectable drug delivery devices market consists of sales of conventional syringes, needle-free injectors, auto-injectors, and pen injectors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.